

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

Measure	Nothing to declare	Nothing new to declare
A, part I	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (i)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (ii)	<input type="checkbox"/>	<input type="checkbox"/>
A, part 2 (iii)	<input type="checkbox"/>	<input type="checkbox"/>
B (i)	<input type="checkbox"/>	<input type="checkbox"/>
B (ii)	<input checked="" type="checkbox"/>	<input type="checkbox"/>
C	<input checked="" type="checkbox"/>	<input type="checkbox"/>
D	<input checked="" type="checkbox"/>	<input type="checkbox"/>
E	<input type="checkbox"/>	<input type="checkbox"/>
F	<input type="checkbox"/>	<input checked="" type="checkbox"/>
G	<input type="checkbox"/>	<input checked="" type="checkbox"/>

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: [Tuesday, 27 April 2010](#)

State Party to the Convention: [Denmark](#)

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility²

Centre for Biosecurity and Biopreparedness (CBB)

2. Responsible public or private organization or company

Ministry of Interior and Health

3. Location and postal address

CBB, Building 10, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

The funding is strictly public and amounts to 21 million Danish crowns annually from the Danish Government. Additional funds have been provided through framework programmes of the European Union.

5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)

None

6. If no maximum containment unit, indicate highest level of protection

BSL 2

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

The objectives of the research programmes include development (or improvement when applicable) of risk and threat assessments, biosecurity, disease surveillance, dispersal assessments, pathogenicity and virulence, sampling techniques, diagnostic techniques, forensic procedures, physical protection and decontamination.

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Yes

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

National biological defence research and development programme

Description

1. State the objectives and funding of the programme and summarize the principal research and development activities conducted in the programme. Areas to be addressed shall include: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

Centre for Biosecurity and Biopreparedness conducts a biological preparedness programme funded by the Danish Government. The Centre is also the National Agency on biosecurity (Act no 474 of 17th of June 2008). The Centre operates as a department of Statens Serum Institut, which reports to the Ministry of Interior and Health.

The objectives of the research programmes include development (or improvement when applicable) of risk and threat assessments, biosecurity, disease surveillance, dispersal assessments, pathogenicity and virulence, sampling techniques, diagnostic techniques, forensic procedures, physical protection and decontamination.

2. State the total funding for the programme and its source.

Approximately 21 million Danish crowns in state funding and ½ million crowns in EU project funding.


3. Are aspects of this programme conducted under contract with industry, academic institutions, or in other non-defence facilities?

No

4. If yes, what proportion of the total funds for the programme is expended in these contracted or other facilities?

5. Summarize the objectives and research areas of the programme performed by contractors and in other facilities with the funds identified under paragraph 4.

6. Provide a diagram of the organizational structure of the programme and the reporting relationships (include individual facilities participating in the programme).



7. Provide a declaration in accordance with Form A, part 2 (iii) for each facility, both governmental and non-governmental, which has a substantial proportion of its resources devoted to the national biological defence research and development programme, within the territory of the reporting State, or under its jurisdiction or control anywhere.

National biological defence research and development programme

Facilities

Complete a form for each facility declared in accordance with paragraph 7 in Form A, part 2 (ii).

In shared facilities, provide the following information for the biological defence research and development portion only.

1. What is the name of the facility?

Centre for Biosecurity and Biopreparedness (CBB)

2. Where is it located (include both address and geographical location)?

Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark

3. Floor area of laboratory areas by containment level:

BL2 2x16 sqM

BL3

BL4

Total laboratory floor area: 32 for dedicated use (sqM)

4. The organizational structure of each facility.

(I)	Total number of personnel	Approx. 25 full time employees and 15 part-time
-----	---------------------------	--

(ii) Division of personnel:

Military

Civilian

100%

(iii) Division of personnel by category:

Scientists

Engineers

10 full time, 5 part time

2 full time

Technicians

4 full time, 10 part time

Administration and support staff

6 full time

- (iv) List the scientific disciplines represented in the scientific/engineering staff.

Bacteriology, biochemistry, chemistry, genetics, immunology, medicine, modelling, molecular biology, parasitology, veterinary medicine, virology, computer science

- (v) Are contractor staff working in the facility? If so, provide an approximate number.

1 scientist involved in an EU project

- (vi) What is (are) the source(s) of funding for the work conducted in the facility, including indication if activity is wholly or partly financed by the Ministry of Defence?

State Funding and EU project funding. No CBB work is funded by MoD

- (vii) What are the funding levels for the following programme areas:

	Approximately
Research	0.5 M _____
Development	0.5 M _____
Test and evaluation	0.5 M _____

- (viii) Briefly describe the publication policy of the facility:

Publication is encouraged if the material is found suitable and not classified; however, publication is not a main priority.

- (ix) Provide a list of publicly-available papers and reports resulting from the work during the previous 12 months. (To include authors, titles and full references.)

CORPS report

BIOSAFE report

AEROBACTICS report

5. Briefly describe the biological defence work carried out at the facility, including type(s) of micro-organisms* and/or toxins studied, as well as outdoor studies of biological aerosols.

Inactivation experiments

As it would be desirable to be able to handle diagnostics of unknown material at BSL2 and 3 laboratories, experiments are being conducted to inactivate bacteria, viruses and toxins before analysis. Experiments have been carried out to verify inactivation of spores with a CBB standard decontamination liquid. For these experiments non-pathogenic/attenuated viruses and bacteria as well as botox og ricin from our collaborating laboratories have been used.

Synthetic DNA

A project on environmental content of virulent plasmids has been carried out and a publication submitted.

Particle characterisation

Properties of microbial particles are being examined.

*Including viruses and prions.

**Background information on outbreaks of reportable
infectious diseases in humans (Denmark)**

Disease	Number of cases per year				
	2005	2006	2007	2008	2009
Only those reportable diseases with outbreaks within the past 5 years have been included					
Anthrax	0	0	0	0	0
Botulism	0	0	0	1	0
Cholera	0	0	0	1	0
Congenital rubella			?	0	0
Creutzfeldt-Jakob	2	23	7	6	8
Corynebacteria diphtheria (Diphtheria)	0	0	0	0	0
Hepatitis A	0	0	25	44	38
HIV	265	245	308	AIDS 40	AIDS 34
Hæmorrhagic fever (Lassa, Marburg, Ebola)	0	0	0	0	0
Hæmolytisk uræmisk syndr.			?	4	5
Legionella pneumoni	111	130	116	130	126
Lepra	0	0	0	0	0
Leptospirose	11	8	13	8	1
Measles	2	27	2	14	6
Meningococ	89	75	62	64	73
Mumps	11	13	11	24	17
Neuroborreliosis	89	100	95	44	61
Ornitosis	22	8	11	7	12
Plague	0	0	0	0	0
Polio	0	0	0	0	0
Purulent meningitis	217	176	156	115	
Rabies	0	0	0	0	0
Rickettsia prowazekii	0	0	2		
SARS	0	0	0	0	0
Shigellosis	109	64	336	90	105
Tetanus			0	2	0
Tuberculosis	429	388	381	361	338
Typhoid/paratyphoid fever	37	23	?	31	30
VTEC/HUS	151	142	164	144	152
Whooping cough in children < 2 years	129	49	78	106	88
Small hive beetle (Aethina tumida)	0	0	0	0	0

Source: http://www.ssi.dk/graphics/dk/nyheder/epinyt/2010/PDF/epinyt_14_2010.pdf

**Background information on outbreaks of reportable
infectious diseases in animals (Denmark)**

Disease	Number of cases per year				
	2005	2006	2007	2008	2009
*=herds					
Only those reportable diseases with outbreaks within the past 4 years have been included					
Multiple species diseases					
Bluetongue	0	0	1	15	0
Anthrax	0	0	0	0	0
Foot-and-mouth disease	0	0	0	0	0
Rabies (other than bats)	0	1	0	0	1
Rift Valley fever	0	0	0	0	0
Vesicular stomatitis	0	0	0	0	0
Brucellosis	0	0	0	0	0
Tuberculosis (bovine/human)	0	0	0	0	0
Bovine Spongiform encephalopathy (BSE)	1	0	0	0	1
Scrapie	0	3	0	1	0
Hydatid disease (Echinococcus granulosus)	0	0	0	0	0
Echinococcus multilocularis	0	0	0	0	0
Salmonellosis	31	41	50	+	+
Trichinella	0	0	0	0	0
Fowl tuberculosis	2	0	0	0	0
Aujeszky's disease	0	0	0	0	0
Leptospirosis (Weil's disease)	+	+	+	+	+
Q-fever	?	?	1	10	1
Deer diseases					
Epizootic hemorrhagic disease of deer	0	0	0	0	0
Cattle diseases					
Rinderpest	0	0	0	0	0
Lumpy skin disease	0	0	0	0	0
Contagious bovine pleuropneumonia	0	0	0	0	0
Cysticercus bovis sive inermis	+	+	+	+	+
Enzootic bovine leukosis	0	0	0	0	0
Bovine herpes virus 1	1	0	0	0	0

Hypoderma bovis	0	0	0	0	0
Parafilaria bovicola	0	0	0	0	0
Bovine virus diarrhea (BVD)	+	+	+	3	+
Swine diseases					
African swine fever	0	0	0	0	0
Classical swine fever	0	0	0	0	0
Swine vesicular disease	0	0	0	0	0
Teschen disease	0	0	0	0	0
Pork bladder worm (Cysticercus cellulosae)	0	0	0	0	0
Transmissible gastroenteritis	0	0	0	0	0
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)	+	+	+	+	+
Sheep and goat diseases					
Sheep and goat pox (Capripox)	0	0	0	0	0
Peste des petits ruminants	0	0	0	0	0
Jaagziekte	0	0	0	0	0
Lymphadenitis (Corynebacterium pseudotuberculosis)	0	0	0	0	0
Morel's disease (Staphylococcus aureus)	0	0	0	0	0
Maedi-visna-virus (lentivirus)	+	+	+	+	+
Equine diseases					
African horse sickness	0	0	0	0	0
Glanders	0	0	0	0	0
Dourine	0	0	0	0	0
Equine encephalomyelitis	0	0	0	0	0
Equine infectious anaemia	0	0	0	0	0
Contagious equine metritis (CEM)	0	0	0	0	0
Epizootic lymphangitis	0	0	0	0	0
Poultry diseases					
Avian influenza, poultry (HPAI)	0	1	0	0	0
Avian influenza, wild birds (HPAI)	0	44	0	0	0
Avian influenza, poultry (LPAI)	0	3	0	1	0
Newcastle disease	1	0	0	0	0
Fowl typhoid (Salmonella gallinarum serovar Gallinarum)	0	0	0	0	0

Fowl typhoid (Salmonella gallinarum serovar Pullorum)	5	2	2	3	2
Fowl pox	0	0	0	0	0
Fowl cholera	0	0	1	1	0
Avian chlamydiosis	11	7	16	6	8
Infectious laryngotracheitis	4	10	5	13	5
Paramyxovirus 1 in pigeons	0	0	0	0	0
Diseases in fur animals					
Paramyxovirus	16	23	3	0	0
Mink viral enteritis	6	7	5	3	0
Myxomatosis	0	2	141	0	0
Tularaemia	0	0	0	0	0
Viral Haemorrhagic Disease	0	0	0	0	0
Plasmacytosis	23	14	41	49	44
Diseases in Bats					
Rabies in bats	2	7	2	0	0
Aquatic diseases (fish)					
Infectious salmon anemia	0	0	0	0	0
Viral haemorrhagic septicaemia	6	2	12	6	1
Infectious haematopoietic necrosis	0	0	0	0	0
Epizootic haematopoietic necrosis	0	0	0	0	0
Infectious pancreatic necrosis	+	+	+	+	+
Bacterial Kidney Disease	8	7	0	0	0
Spring Viraemia of Carp	0	0	0	0	0
Aquatic diseases (shellfish)					
Haplosporidiosis	0	0	0	0	0
Perkinosis	0	0	0	0	0
Mikrocytosis	0	0	0	0	0
Iridovirus	0	0	0	0	0
Marteiliosis	0	0	0	0	0
Bonamiosis	0	0	0	0	0
Candidatus Xenohalictis californiensis	0	0	0	0	0
Bee diseases					
American foulbrood	51	69	78	53	38
European foulbrood	1	0	0	0	0
Tropilaelaps mite	0	0	0	0	0
Small hive beetle (Aethina tumida)	0	0	0	0	0

Source: <http://www.foedevarestyrelsen.dk>

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

1. Time of cognizance of the outbreak None.....
2. Location and approximate area affected
3. Type of disease/intoxication
4. Suspected source of disease/
intoxication
5. Possible causative agent(s)
6. Main characteristics of systems
7. Detailed symptoms, when applicable
 - respiratory
 - circulatory
 - neurological/behavioural
 - intestinal
 - dermatological
 - nephrological
 - other
8. Deviation(s) from the normal pattern as regards
 - type
 - development
 - place of occurrence
 - time of occurrence
 - symptoms
 - virulence pattern

- drug resistance pattern
 - agent(s) difficult to diagnose
 - presence of unusual vectors
 - other
9. Approximate number of primary cases
10. Approximate number of total cases
11. Number of deaths
12. Development of the outbreak
13. Measures taken

4. **CONFIDENCE-BUILDING MEASURE "C":**

- **Encouragement of publication of results and promotion of use of knowledge**

At the Third Review Conference it was agreed that States parties continue to implement the following:

"Encouragement of publication of results of biological research directly related to the Convention, in scientific journals generally available to States parties, as well as promotion of use for permitted purposes of knowledge gained in this research."

Modalities

The Third Review Conference agreed on the following:

1. It is recommended that basic research in biosciences, and particularly that directly related to the Convention should generally be unclassified and that applied research to the extent possible, without infringing on national and commercial interests, should also be unclassified.
2. States parties are encouraged to provide information on their policy as regards publication of results of biological research, indicating, *inter alia*, their policies as regards publication of results of research carried out in research centres and laboratories subject to exchange of information under item A and publication of research on outbreaks of diseases covered by item B, and to provide information on relevant scientific journals and other relevant scientific publications generally available to States parties.
3. The Third Review Conference discussed the question of cooperation and assistance as regards the safe handling of biological material covered by the Convention. It concluded that other international forums were engaged in this field and expressed its support for efforts aimed at enhancing such cooperation.

Active promotion of contacts

1. Planned international conferences, symposia, seminars, and other similar forums for exchange

For each such event, the following information should be provided:

- name of the conference, etc.
- arranging organization(s), etc.
- time
- place
- main subject(s) for the conference, etc.
.....
- conditions for participation
- point of contact for further information, registration, etc.
.....
.....

2. Information regarding other opportunities

.....
.....
.....

Declaration of legislation, regulations and other measures

<u>Relating to</u>	<u>Legislation</u>	<u>Regulations</u>	<u>Other measures</u>	<u>Amended since last year</u>
(a) Development, production stockpiling, acquisition or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I	YES	YES	NO	YES
(b) Exports of micro-organisms* and toxins	YES	YES	NO	NO
(c) Imports of micro-organisms* and toxins	YES	YES	NO	NO

Act no 474 of 17th of June 2008 on securing certain biological agents, means of delivery and related materials.

Executive Order no 981 of 15th of October 2009 on securing certain biological agents, means of delivery and related materials.

.

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention.

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.
1973

2. Past offensive biological research and development programmes:

- NO
- Period(s) of activities
- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:

- YES
- Period(s) of activities
- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Denmark has since 2001 maintained and expanded an ongoing national capability within defensive biological research and development. For a summary of research and development activities please refer to Part 2: Exchange information on national biological defence research and development programmes, described in the section termed Confidence-building measure A.

-

Declaration of vaccine production facilities

1. Name of facility:

Statens Serum Institut

Declaration of governmental vaccine production facilities for the protection of humans.

2. Location (mailing address):

Statens Serum Institut

Artillerivej 5

2300 Copenhagen S

Denmark

3. General description of the types of diseases covered:

Vaccine production includes polio vaccine, tetanus, diphtheria, pertussis and tuberculosis.

Declaration of vaccine production facilities

1. Name of facility:

Bavarian Nordic A/S

Declaration of corporate vaccine production facilities for the protection of humans.

2. Location (mailing address):

Bavarian Nordic A/S

Bøgeskovvej 9

3490 Kvistgård

Denmark

3. General description of the types of diseases covered:

Vaccine production includes smallpox vaccine (Modified Vaccinia Ankara). Manufacturing capability amounts to the production of 40 million doses annually.